What can rodent activity tell us about methamphetamine abuse?

Methamphetamines: Abuse, Health Effects and Treatment Options

Volumn , Issue , 2012, Pages 47-82

  Sage, Andrew S ^a   Miller, Dennis K ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884381371     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (75)

1. Ago, Y., Arikawa, S., Yata, M., Yano, K., Abe, M., Takuma, K., et al. (2009). Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyper-activity. Synapse, 63(1), 7-14.
2. Ago, Y., Nakamura, S., Baba, A., & Matsuda, T. (2008). Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine-and cocaine-induced behavioral sensitization in mice. J Pharmacol Sci, 106(1), 15-21.
3. Ago, Y., Nakamura, S., Kajita, N., Uda, M., Hashimoto, H., Baba, A., et al. (2007). Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice. Synapse, 61(9), 757-763.
4. Ago, Y., Nakamura, S., Uda, M., Kajii, Y., Abe, M., Baba, A., et al. (2006). Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology, 51(4), 914-922.
5. Bardo, M. T., Donohew, R. L., & Harrington, N. G. (1996). Psychobiology of novelty seeking and drug seeking behavior. Behavioral Brain Research, 77, 23-43.
6. Bevins, R. A., & Peterson, J. L. (2004). Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine. Pharmacol Biochem Behav, 79(1), 65-74.
7. Brennan, K., Johnstone, A., Fitzmaurice, P., Lea, R., & Schenk, S. (2007). Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend, 88(2-3), 204-213.
8. Byrnes-Blake, K. A., Laurenzana, E. M., Carroll, F. I., Abraham, P., Gentry, W. B., Landes, R. D., et al. (2003). Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol, 461(2-3), 119-128.
9. Camarasa, J., Rates, S. G., Pubill, D., & Escubedo, E. (2009). The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice. Behav Pharmacol, 20(7), 623-630.
10. Comings, D. E., & Blum, K. (2000). Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res, 126, 325-341.
11. Dluzen, D. E., & Liu, B. (2008). Gender differences in methamphetamine use and responses: a review. Gend Med, 5(1), 24-35.
12. Dobbs, L. K., & Mark, G. P. (2008). Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. Neuroscience, 156(3), 700-711.
13. Fornai, F., Biagioni, F., Fulceri, F., Murri, L., Ruggieri, S., & Paparelli, A. (2009). Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism. Int Rev Neurobiol, 88, 371-398.
14. Fukushima, S., Shen, H., Hata, H., Ohara, A., Ohmi, K., Ikeda, K., et al. (2007). Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl), 193(1), 55-62.
15. Ginawi, O. T., Al-Majed, A. A., & Al-Suwailem, A. K. (2005). NAN-190, a possible specific antagonist for methamphetamine. Regul Toxicol Pharmacol, 41(2), 122-127.
16. Ginawi, O. T., Al-Majed, A. A., Al-Suwailem, A. K., & El-Hadiyah, T. M. (2004). Involvement of some 5-HT receptors in methamphetamine-induced locomotor activity in mice. J Physiol Pharmacol, 55(2), 357-369.
17. Glickstein, S. B., & Schmauss, C. (2004). Effect of methamphetamine on cognition and repetitive motor behavior of mice deficient for dopamine D2 and D3 receptors. Ann N Y Acad Sci, 1025, 110-118.
18. Glickstein, S. B., & Schmauss, C. (2004). Focused motor stereotypies do not require enhanced activation of neurons in striosomes. J Comp Neurol, 469(2), 227-238.
19. Graybiel, A. M., Aosaki, T., Flaherty, A. W., & Kimura, M. (1994). The basal ganglia and adaptive motor control. Science, 265(5180), 1826-1831.
20. Hagino, Y., Kasai, S., Han, W., Yamamoto, H., Nabeshima, T., Mishina, M., et al. (2010). Essential role of NMDA receptor channel epsilon4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine. PLoS One, 5(10), e13722.
21. Haile, C. N., Kosten, T. R., & Kosten, T. A. (2009). Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and metham-phetamine. Am J Drug Alcohol Abuse, 35(3), 161-177.
22. Hunt, D., (2006). Methamphetamine Abuse: Challenges for Law Enforcement and Communities (NCJ 214117). National Institute of Justice (NIJ), Washington, DC: Government Printing Office.
23. Inoue, I., Yanai, K., Kitamura, D., Taniuchi, I., Kobayashi, T., Niimura, K., et al. (1996). Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A, 93(23), 13316-13320.
24. Ishiguro, H., Horiuchi, Y., Ishikawa, M., Koga, M., Imai, K., Suzuki, Y., et al. (2010). Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry, 67(10), 974-982.
25. Ito, S., Mori, T., Namiki, M., Suzuki, T., & Sawaguchi, T. (2007). Complicated interaction between psychostimulants and morphine in expression of phenotype of behavior in the dopaminergic system of BALB/c mice. J Pharmacol Sci, 105(4), 326-333.
26. Itzhak, Y., Martin, J. L., & Ali, S. F. (2000). Comparison between the role of the neuronal and inducible nitric oxide synthase in methamphetamine-induced neurotoxicity and sensitization. Ann N Y Acad Sci, 914, 104-111.
27. Iwabuchi, K., Kubota, Y., Ito, C., Watanabe, T., & Yanai, K. (2004). Methamphetamine and brain histamine: a study using histamine-related gene knockout mice. Ann N Y Acad Sci, 1025, 129-134.
28. Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (1995). Essentials of neural science and behavior. McGraw-Hill Professional.
29. Kamens, H. M., & Phillips, T. J. (2008). A role for neuronal nicotinic acetylcholine receptors in ethanol-induced stimulation, but not cocaine-or methamphetamine-induced stimulation. Psychopharmacology (Berl), 196(3), 377-387.
30. Kelly, M. A., Low, M. J., Rubinstein, M., & Phillips, T. J. (2008). Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice. Genes Brain Behav, 7(5), 568-577.
31. Kitanaka, N., Kitanaka, J., & Takemura, M. (2005). Repeated clorgyline treatment inhibits methamphetamine-induced behavioral sensitization in mice. Neurochem Res, 30(4), 445-451.
32. Kobayashi, K., & Sano, H. (2000). Dopamine deficiency in mice. Brain Dev, 22 Suppl 1, S54-60.
33. Krasnova, I. N., Betts, E. S., Dada, A., Jefferson, A., Ladenheim, B., Becker, K. G., et al. (2007). Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox Res, 11(2), 107-130.
34. Krasnova, I. N., Hodges, A. B., Ladenheim, B., Rhoades, R., Phillip, C. G., Cesena, A., et al. (2009). Methamphetamine treatment causes delayed decrease in novelty-induced locomotor activity in mice. Neurosci Res, 65(2), 160-165.
35. Kubota, Y., Ito, C., Sakurai, E., Watanabe, T., & Ohtsu, H. (2002). Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J Neurochem, 83(4), 837-845.
36. Kuczenski, R., & Segal, D. S. (2002). Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci, 22(16), 7264-7271.
37. Landa, L., Slais, K., & Sulcova, A. (2006). Impact of cannabinoid receptor ligands on behavioural sensitization to antiaggressive methamphetamine effects in the model of mouse agonistic behaviour. Neuro Endocrinol Lett, 27(6), 703-710.
38. Li, J. X., Han, R., Deng, Y. P., Chen, S. Q., & Liang, J. H. (2005). Different effects of valproate on methamphetamine-and cocaine-induced behavioral sensitization in mice. Behav Brain Res, 161(1), 125-132.
39. Matsumoto, R. R., Shaikh, J., Wilson, L. L., Vedam, S., & Coop, A. (2008). Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol, 18(12), 871-881.
40. Mori, T., Ito, S., Kita, T., Narita, M., Suzuki, T., & Sawaguchi, T. (2006). Effects of mu-, delta-and kappa-opioid receptor agonists on methamphetamine-induced self-injurious behavior in mice. Eur J Pharmacol, 532(1-2), 81-87.
41. Nakagawa, T., Fujio, M., Ozawa, T., Minami, M., & Satoh, M. (2005). Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice. Behav Brain Res, 156(2), 233-239.
42. Nguyen, E. C., McCracken, K. A., Liu, Y., Pouw, B., & Matsumoto, R. R. (2005). Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuro-pharmacology, 49(5), 638-645.
43. Okuda, T., Zhang, D., Shao, H., Okamura, N., Takino, N., Iwamura, T., et al. (2009). Methamphetamine-and 3, 4-methylenedioxymethamphetamine-induced behavioral changes in histamine H3-receptor knockout mice. J Pharmacol Sci, 111(2), 167-174.
44. Okuyama, S., Chaki, S., Yoshikawa, R., Suzuki, Y., Ogawa, S., Imagawa, Y., et al. (1997). In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). J Pharmacol Exp Ther, 282(1), 56-63.
45. Picard, M., Morisset, S., Cloix, J. F., Bizot, J. C., Guerin, M., Beneteau, V., et al. (2010). Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist. Neuroscience, 169(3), 1337-1346.
46. Pickens, R., & Thompson, T. (1968). Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size. J Pharmacol Exp Ther, 161(1), 122-129.
47. Polston, J. E., Cunningham, C. S., Rodvelt, K. R., & Miller, D. K. (2006). Lobeline augments and inhibits cocaine-induced hyperactivity in rats. Life Sci, 79(10), 981-990.
48. Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews, 18(3), 247-291.
49. Robinson, T. E., & Berridge, K. C. (2000). The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction, 95, S91-S117.
50. Robinson, T. E., & Berridge, K. C. (2001). Mechanisms of action of addictive stimuli: Incentive-sensitization and addiction. Addiction, 96, 103-114.
51. Rodvelt, K. R., Oelrichs, C. E., Blount, L. R., Fan, K. H., Lever, S. Z., Lever, J. R., et al. (2011). The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine. Drug Alcohol Depend.
52. Rubinstein, M., Phillips, T. J., Bunzow, J. R., Falzone, T. L., Dziewczapolski, G., Zhang, G., et al. (1997). Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell, 90(6), 991-1001.
53. Scibelli, A. C., McKinnon, C. S., Reed, C., Burkhart-Kasch, S., Li, N., Baba, H., et al. (2011). Selective breeding for magnitude of methamphetamine-induced sensitization alters methamphetamine consumption. Psychopharmacology (Berl), 214(4), 791-804.
54. Shadrina, M. I., Slominsky, P. A., & Limborska, S. A. (2010). Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol, 281, 229-266.
55. Shen, X., Purser, C., Tien, L. T., Chiu, C. T., Paul, I. A., Baker, R., et al. (2010). mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. J Neurosci Res, 88(10), 2294-2302.
56. Shimosato, K., Nagao, N., Watanabe, S., & Kitayama, S. (2003). Suppressive effects of trihexyphenidyl on methamphetamine-induced dopamine release as measured by in vivo microdialysis. Synapse, 49(1), 47-54.
57. Shimosato, K., Watanabe, S., & Kitayama, S. (2001). Differential effects of trihexyphenidyl on place preference conditioning and locomotor stimulant activity of cocaine and methamphetamine. Naunyn Schmiedebergs Arch Pharmacol, 364(1), 74-80.
58. Steinkellner, T., Freissmuth, M., Sitte, H. H., & Montgomery, T. (2011). The ugly side of amphetamines: short-and long-term toxicity of 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem, 392(1-2), 103-115.
59. Tabibnia, G., Monterosso, J. R., Baicy, K., Aron, A. R., Poldrack, R. A., Chakrapani, S., et al. (2011). Different forms of self-control share a neurocognitive substrate. J Neurosci, 31(13), 4805-4810.
60. Takamatsu, Y., Yamamoto, H., Ogai, Y., Hagino, Y., Markou, A., & Ikeda, K. (2006). Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann N Y Acad Sci, 1074, 295-302.
61. Thomas, D.L. Introduction to Addictive Behaviors (3rd Edition, 2006) New York: The Guilford Press.
62. Toyota, H., Dugovic, C., Koehl, M., Laposky, A. D., Weber, C., Ngo, K., et al. (2002). Behavioral characterization of mice lacking histamine H(3) receptors. Mol Pharmacol, 62(2), 389-397.
63. Ungard, J. T., Beekman, M., Gasior, M., Carter, R. B., Dijkstra, D., & Witkin, J. M. (2000). Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology (Berl), 148(4), 336-343.
64. United Nations Office on Drugs and Crime (U.N.O.D.C.). (2009). World Drug Report. United Nations, New York: Government Printing Office.
65. U.S. Department of Justice (U.S.DoJ), National Drug Intelligence Center. (2010). National Drug Threat Assessment (2010-Q0317-001). Johnstown, PA: Government Printing Office.
66. Vezina, P. (2004). Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev, 27(8), 827-839.
67. Winger, G., Woods, J. H., & Hofmann, F. G. A Handbook on Drug and Alcohol Abuse (4th Edition, 2004) Oxford: Oxford University Press.
68. Wise, R. A. (1998). Drug-activation of brain reward pathways. Drug Alcohol Depend, 51(1-2), 13-22.
69. Wise, R. A. (2002). Brain reward circuitry: insights from unsensed incentives. Neuron, 36(2), 229-240.
70. Wise, R. A., & Bozarth, M. A. (1987). A psychomotor stimulant theory of addiction. Psychological Review, 94(4), 469-492.
71. Yamanaka, Y., Yamamoto, T., & Egashira, T. (1983). Methamphetamine-induced behavioral effects and releases of brain catecholamines and brain concentrations of methamphetamine in mice. Jpn J Pharmacol, 33(1), 33-40.
72. Yoo, J. H., Lee, H. K., Kim, H. C., Lee, S. Y., & Jang, C. G. (2010). GABA(A) receptors mediate the attenuating effects of a 5-HT(3) receptor antagonist on methamphetamine-induced behavioral sensitization in mice. Synapse, 64(4), 274-279.
73. Yoo, J. H., Nam, Y. S., Lee, S. Y., & Jang, C. G. (2008). Dopamine neurotransmission is involved in the attenuating effects of 5-HT3 receptor antagonist MDL 72222 on acute methamphetamine-induced locomotor hyperactivity in mice. Synapse, 62(1), 8-13.
74. Zombeck, J. A., Gupta, T., & Rhodes, J. S. (2009). Evaluation of a pharmacokinetic hypothesis for reduced locomotor stimulation from methamphetamine and cocaine in adolescent versus adult male C57BL/6J mice. Psychopharmacology (Berl), 201(4), 589-599.
75. Zombeck, J. A., Lewicki, A. D., Patel, K., Gupta, T., & Rhodes, J. S. (2010). Patterns of neural activity associated with differential acute locomotor stimulation to cocaine and methamphetamine in adolescent versus adult male C57BL/6J mice. Neuroscience, 165(4), 1087-1099.